Novartis to Acquire Arctos to Boost its Optogenetics Portfolio to Treat Eye Diseases

 Novartis to Acquire Arctos to Boost its Optogenetics Portfolio to Treat Eye Diseases

Novartis Presented Results of Remibrutinib (LOU064) in P-IIb Study for the Treatment of Chronic Spontaneous Urticaria at EADV

Shots:

  • The acquisition expands Novartis’ ophthalmology portfolio with the addition of Arctos’ pre-clinical optogenetics-based AAV gene therapy program and its technology
  • The acquisition marks the Novartis commitment to identify optogenetics-based therapies for the treatment of patients with vision loss
  • Arctos has developed its technology to treat IRDs and other diseases that involve photoreceptor loss, such as AMD. Arctos’ optogene is delivered to specific retinal cells using gene therapy to convert targeted cells into replacement photoreceptor-like cells

Click here to­ read full press release/ article | Ref: Novartis | Image: Reuters

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post